1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Tern-701: new trials by email Literature Review of Tern-701 trials Research Report on Tern-701
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) MK-4208 - Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Recruiting | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 330 | 2024-03-26 | 2026-10-15 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Chronic-Phase (1)
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
Australia (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
2023 (1)